Relay Therapeutics to Participate in Upcoming Investor Conferences
CAMBRIDGE, Mass., Nov. 07, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today announced that management will participate in the following upcoming fireside chats:
- Guggenheim Healthcare Innovation Conference on Wednesday, November 13, 2024 at 10:00 a.m. ET
- Stifel 2024 Healthcare Conference on Monday, November 18, 2024 at 10:55 a.m. ET
- Jefferies London Healthcare Conference on Wednesday, November 20, 2024 at 6:30 a.m. ET (11:30 a.m. GMT)
- The Citizens JMP Hematology and Oncology Summit, taking place virtually on Monday, December 2, 2024 at 1:30 p.m. ET
The fireside chats will be webcast live and may be accessed through Relay Therapeutics’ website under Events in the News & Events section through the following link: . An archived replay of the webcast will be available for up to 30 days following the event.
About Relay Therapeutics
Relay Therapeutics (Nasdaq: RLAY) is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. As the first of a new breed of biotech created at the intersection of complementary techniques and technologies, Relay Therapeutics aims to push the boundaries of what’s possible in drug discovery. Its Dynamo® platform integrates an array of leading-edge computational and experimental approaches designed to drug protein targets that have previously been intractable or inadequately addressed. Relay Therapeutics’ initial focus is on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. For more information, please visit or .
Contact:
Megan Goulart
617-545-5526
Media:
Dan Budwick
1AB
973-271-6085
